KOD — Kodiak Sciences Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1468748 ·
Last close
$37.22
Market Cap
$2.34B
52W High
$46.87
52W Low
$29.21
ADV30
571,419
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -59,777,000 | -58,158,000 | 306,006,000 | 169,530,000 | 193,905,000 |
| Dec 2025 | 0 | — | -57,453,000 | -56,736,000 | 351,533,000 | 209,862,000 | 194,150,000 |
| Sep 2025 | 0 | — | -62,352,000 | -61,457,000 | 218,069,000 | 72,038,000 | 194,377,000 |
| Jun 2025 | 0 | — | -55,510,000 | -54,313,000 | 256,725,000 | 104,165,000 | 186,435,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-146,940,000
Investing CF
$-1,178,000
Financing CF
$178,797,000
CapEx
$-1,178,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.17
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,616,863,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-230,671,000
Pretax Income TTM
$-230,664,000
Interest Exp TTM
$0
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -234,388,000 | -229,967,000 | 351,533,000 | 194,150,000 | — | -136,008,000 |
| Dec 2024 | 0 | -186,849,000 | -176,207,000 | 335,578,000 | 185,290,000 | — | -117,319,000 |
| Dec 2023 | 0 | -277,321,000 | -260,491,000 | 479,372,000 | 213,591,000 | — | -154,183,000 |
| Dec 2022 | 0 | -341,379,000 | -333,823,000 | 666,628,000 | 230,461,000 | — | -206,459,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.55
Max Pain — expiry 2026-09-18
max pain strike: $35.00 · spot: $37.22 · call oi: 2,213 · put oi: 3,384
Expected Move to 2026-09-18:
±$6.80
(18.27%) —
implied range
$30.42 –
$44.02
· ATM straddle on $37.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MEOBF | MESOBLAST LTD | $2.45B | $1.89 | — |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $2.47B | $9.68 | — |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.18B | $46.67 | — |
| VCEL | Vericel Corp | $2.17B | $42.30 | — |
| MESO | MESOBLAST LTD | $2.16B | $16.64 | — |
News headlines (Yahoo Finance, 1h cache)
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results
2026-08-13 20:00 · Yahoo
Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
2026-08-10 20:35 · Yahoo
Kodiak CFO Sells $1 Million in Stock as Shares Surge 650%. What Investors Should Know
2026-06-10 00:04 · Yahoo
Kodiak Sciences (KOD) Is Down 15.4% After Strong Zenkuda GLOW2 Data And Accelerated Filing Plans
2026-06-06 13:18 · Yahoo
Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference
2026-05-28 22:09 · Yahoo
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally
2026-05-17 20:17 · Yahoo
A Look At Kodiak Sciences (KOD) Valuation After Positive Phase 3 GLOW2 Results For Zenkuda
2026-05-11 01:14 · Yahoo
Zenkuda Phase 3 Win and Expanding Pipeline Might Change The Case For Investing In Kodiak Sciences (KOD)
2026-05-10 19:09 · Yahoo
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
2026-05-07 20:00 · Yahoo
Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences
2026-05-01 04:23 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.